Traws Pharma Inc./$TRAW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Traws Pharma Inc.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Ticker
$TRAW
Sector
Primary listing
Employees
6
Headquarters
Website
TRAW Metrics
BasicAdvanced
$12m
-
-$1.52
1.47
-
Price and volume
Market cap
$12m
Beta
1.47
52-week high
$3.27
52-week low
$0.64
Average daily volume
4.6m
Financial strength
Current ratio
0.429
Quick ratio
0.365
Profitability
EBITDA (TTM)
-19.514
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-710.83%
Operating margin (TTM)
-717.82%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-90.09%
Return on equity (TTM)
-5,639.19%
Valuation
Price to revenue (TTM)
2.672
Price to book
-1.53
Price to tangible book (TTM)
-1.04
Price to free cash flow (TTM)
-0.408
Free cash flow yield (TTM)
-245.21%
Free cash flow per share (TTM)
-1.958
Growth
Revenue change (TTM)
1,103.96%
Earnings per share change (TTM)
-81.72%
3-year revenue growth (CAGR)
129.53%
10-year revenue growth (CAGR)
-14.32%
3-year earnings per share growth (CAGR)
-60.52%
TRAW News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs